Cell-permeable cyclin-dependent kinase inhibitor. IC50
values are 0.033, 0.033, 0.028 and 0.020 μ
M for cdk1/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5/p35 respectively. Inhibits ERK1 (IC50
= 12.0 μ
M) and ERK2 (IC50
= 3.1 μ
M) and is 3000-fold selective over a range of other protein kinases (IC50
> 100 μ
M). Arrests cell cycle at G2
/M boundary (IC50
= 1.25 μ
M), and induces apoptosis at concentrations > 10 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from the Regents of the University of California
Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang et al.
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.
Knockaert et al.
A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts.
Rosiana et al.